OIPE Form PTO-1449 (Modified) MAR 0 5 2002 INFORMATION DISCRESSIVE STATEMENT

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 27129/33783B Serial No. 09/994,185

Applicant

White et al.

Filing Date November 26, 2001 Group **TBD**

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS Filing Date Name Subclass If Class **Document** *Examiner Issue Appropriate Number Initials Date White 01/16/96 **A1** 5,484,705 Ulevitch **A2** 5,245,013 09/14/93 Ulevitch 05/10/94 **A3** 5,310,879

						Tran	slation
	Document Number	Publication Date	Country	Class	Subclass	Yes	No
B1	WO 91/01639	02/21/91	PCT				
B2	WO 93/06228	04/01/93	PCT				
В3	WO 94/21280	09/29/94	PCT	. (
B4	WO 94/25476	11/10/94	PCT)			
B5	WO 95/00641	01/05/95	PCT				
В6	WO 95/02414	01/26/95	PCT				
	B2 B3 B4 B5	Number B1 WO 91/01639 B2 WO 93/06228 B3 WO 94/21280 B4 WO 94/25476 B5 WO 95/00641	Number Date B1 WO 91/01639 02/21/91 B2 WO 93/06228 04/01/93 B3 WO 94/21280 09/29/94 B4 WO 94/25476 11/10/94 B5 WO 95/00641 01/05/95	Number Date B1 WO 91/01639 02/21/91 PCT B2 WO 93/06228 04/01/93 PCT B3 WO 94/21280 09/29/94 PCT B4 WO 94/25476 11/10/94 PCT B5 WO 95/00641 01/05/95 PCT	Number Date B1 WO 91/01639 02/21/91 PCT B2 WO 93/06228 04/01/93 PCT B3 WO 94/21280 09/29/94 PCT B4 WO 94/25476 11/10/94 PCT B5 WO 95/00641 01/05/95 PCT	Number Date B1 WO 91/01639 02/21/91 PCT B2 WO 93/06228 04/01/93 PCT B3 WO 94/21280 09/29/94 PCT B4 WO 94/25476 11/10/94 PCT B5 WO 95/00641 01/05/95 PCT	Document Number Publication Date Country Class Subclass Yes

EXAMINER	1 aren	A. Cam	lle	DATE CONSIDERED	11/2/2004

*EXAMINER:/Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27129/33783B

Sérial No. 09/994,185

Applicant

White et al.

Filing Date November 26, 2001 Group **TBD**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Dofferhoff et al., "Tumor necrosis factor (cachectin) and other cytokines in septic C1 shock: a review of the literature", Netherlands J. Med., 39:45-62 (1991). C2 Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeabilityincreasing Protein and a Closely Associated Phospholipase A2 from Rabbit Polymorphonuclear Leukocytes", J. Biol. Chem., 254(21):11000-11009 (November 10, 1979). **C3** Erwin and Munford, "Plasma Lipopolysaccharide-Deacylating Activity (Acyloxyacyl Hydrolase) Increases After Lipopolysaccharide Administration to Rabbits", Lab. Invest., 65(2):138-144 (1991). C4 Gallay et al., "Purification and Characterization of Murine Lipopolysaccharide-Binding Protein", Infect. Immun. 61(2):378-383 (February 1993). **C5** Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", Infect. Immun. 60(11):4754-4761 (November 1992). **C6** Leturcq et al, "Generation of Monoclonal Antibodies to Human LBP and Their Use in the Detection of LBP Protein in Serum", J. Cell. Biochem., 16C:161 (1992). **C7** Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", J. Immun., 148(2):532-537 (January 15, 1992). **C8** Pereira et al, "Quantitation of a cationic antimicrobial granule protein of human polymorphonuclear leukocytes by ELISA", J. Immunol. Methods, 117:115-120 (1989).Pesce et al., "Cationic antigens Problems associated with measurement by **C9** ELISA", J. Immunol. Methods, 87:21-27 (1986). **C**10 Schindler et al., "Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis", Clin. Nephrology, 40(6):346-351 (1993).

EXAMINER	Harm	A. Game	lh	DATE CONSIDERED	11/2/2004

*EXAMINER! Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 OF 5 Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office Scrial No. Atty. Docket No. 09/994,185 27129/33783B INFORMATION BUSCLE Applicant White et al. OSTRE STATEMENT Filing Date Group November 26, 2001 **TBD** (Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
KAC	C11	Schumann et al., "Structure and Function of Lipopolysaccharide Binding Protein", Science, 249:1429-1433 (September 21, 1990).
	C12	Spitznzgel, "Antibiotic Proteins of Human Neutrophilia", J. Clin. Invest., 86:1381-1386 (1990).
	C13	Taber et al., Taber's Cyclopedic Medical Dictionary, pp 545 (F.A. Davis Co., Philadelphia) (1985).
	C14	Ulevitch, Presentation at the merican Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993).
	C15	von der Mohien et al., Bactericidal/Permeability-Increasing Protein Levels Predict Survival in Patients with Gram-Negative Sepsis", Abstract presented at 13th International Symposium on Intensive Care and Emergency Medicine, (Brussels, Belgium) (March 1993).
	C16	Weiss and Olsson, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", Blood, 69(2):652-659 (February 1987).
	C17	Weiss et al., "Human Bactericidal/Permeability-Increasing Protein and a Recombinant NH ₂ - Terminal Fragment Cause Killing of Serum-resistant Gramnegative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria", "J. Clin. Invest. 90:1122-1130 (September 1992).
	C18	Weiss et al., "Purification and Characterization of a Potent Bactericidal and Membrane Active Protein from the Granules of Human Polymorphonuclear Leukocytes", J. Biol. Chem., 253(8):2664-2672 (April 25, 1978).
	C19	White et al., "Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA", J. Immunol. Methods, 167:227-235 (1994).
	C20	Wright et al., "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein", Science, 249:1431-1433 (September 21, 1990).
	C21	Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993) (Session 13 Abstract 564).

Mon G. Ganela	EXAMINER AMINI A	DATE CONSIDERED 11/2/20	04
---------------	------------------	-------------------------	----

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 4 OF 5 Serial No. Form PTO-1449 (Modified) U.S. Department of Commerce Atty. Docket No. Paten.

Paten.

Paten. 27129/33783B 09/994,185 INFORMATION DISCLO Applicant White et al. Filing Date Group November 26, 2001 **TBD** (Use several sheets if necessary)

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
KAL	C22	Tobias et al., "Lipopolysaccharide Binding Protein" J. Cell. Biochem., 16 C:151 (Abstract (CB006) (1992)
	C23	Ballou et al., "Laboratory Evaluation of Inflammation," Textbook of Rheumatology, Vol. 1, Ch. 40, pp. 671-679 (1993)
	C24	Baumann et al., "The acute phase response," <i>Immunology Today</i> , Vol. 15, ¼½. 2, pp. 74-80 (1994)
	C25	Grube et al., "Lipopolysaccharide Binding Protein Expression in Primary Human Hepatocytes and HepG2 Hepatoma Cells*," J. Biol. Chem., Vol. 269, No. 11, pp. 8477-8482 (1994)
	C26	Raynes, "Carbohydrate Binding Proteins and Immune Responses," Biochemical Immunology Group/Glycobiology Group Joint Colloquium Organized by G.B. Wisdom and M.I. Halliday (The Queen's University, Belfast) and Edited by G.B. Wisdom. 648th Meeting held at the Queen's University, Belfast, 14-17 September 1993, Biochemical Society Transactions, Vol. 22, pp. 69-74 (1994)
	C27	Meszaros et al., "Immunoreactivity and Bioactivity of Lipopolysaccharide-Binding Protein in Normal and Heat-Inactivated Sera," <i>Infection and Immunity</i> , Vol. 63, No. 1, pp. 363-366 (1995)
	C28	Pugin et al., "Soluble CD14 and Lipopolysaccharide Binding Protein Mediate Epithelial Cell Responses to Lipopolysaccharides," FASEB J., A142 (1993)
	C29	Geller et al., Arch. Surg., 128:22-28 (1993)
	C30	Tobias, J. Biol. Chem., 263:13479-13481 (1988)
	C31	Schumann, Science, 249:1429-1431 (1990)
	C32	Dubin et al., "Asthma and Endotoxin: Lipopolysaccharide-Binding Protein and Soluble CD14 in Bronchoalveolar Compartment," Am. J. Physiol., 270:L736-L744 (1996)
Y	C33	Froon et al., "Lipopolysaccharide Toxicity Regulating Proteins in Bacteremia," J. Infect. Dis., 171:1250-1257 (1995)

EXAMINER JAR	in g.	Janelle	DATE CONSIDERED	11/2/2009
	0.00			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCRESSURE STATEMENT

(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 27129/33783B

Applicant White et al.

Filing Date November 26, 2001

TBD

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
ILAC	C34	Heumann et al., "Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma," J. Immunol. Meth., 171:169-176 (1994)
	C35	Iriye et al., "Differences in the Concentration of an Endotoxin Binding Protein Help Explain Sensitivity to Septic Complications in Pregnancy," Am. J. Obstetrics Gynecol., 174(1 pt. 2):390 (1996)
	C36	Nakayama et al., "Monitoring Both Serum Amyloid Protein A and C-Reactive Proteins as Inflammatory Markers in Infectious Diseases," Clin. Chem. 39:293-297 (1993)
	C37	Schumann et al., 36th Int'l Conf. on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, (1996)

EXAMINER Jamel Jamelle DATE CONSIDERED 11/2/2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.